[Skip to Content]
Outline
Quiz
PDF
Pain Medicine

Opioids for Chronic Noncancer PainA Systematic Review and Meta-analysis

Educational Objective
To review the clinical benefits of opioid therapy.

Related Show All 6

  1. Meta-analysis of Opioids for Chronic Pain

  2. Meta-analysis of Opioids for Chronic Pain

  3. Meta-analysis of Opioids for Chronic Pain—Reply

  4. Random-Effects Meta-analysis

  5. Increasing Evidence for the Limited Role of Opioids to Treat Chronic Noncancer Pain

  6. How Effective are Opioids for Chronic Noncancer Pain?
1 Credit CME
JAMA
December 18, 2018
Original Investigation
Jason W. Busse, DC, PhD1,2,3,4; Li Wang, PhD1,2,5; Mostafa Kamaleldin, MB BCh6; et al Samantha Craigie, MSc3; John J. Riva, DC, MSc3,7; Luis Montoya, DDS, MSc8; Sohail M. Mulla, PhD3,9; Luciane C. Lopes, ScD, MSc10; Nicole Vogel, PhD11; Eric Chen, BHSc12; Karin Kirmayr, MD13; Kyle De Oliveira, MD14; Lori Olivieri, MD15; Alka Kaushal, MBBS, DA1,3,16; Luis E. Chaparro, MD17; Inna Oyberman, MD17; Arnav Agarwal, MD3,18; Rachel Couban, MA, MISt1; Ludwig Tsoi, MBChB19; Tommy Lam, MBBS20; Per Olav Vandvik, MD, PhD21; Sandy Hsu, BA3; Malgorzata M. Bala, MD22; Stefan Schandelmaier, MD3,23,24; Anne Scheidecker, MD2,25; Shanil Ebrahim, PhD3; Vahid Ashoorion, MD, PhD1,26; Yasir Rehman, MD, MSc1,27; Patrick J. Hong, BMSc28; Stephanie Ross, PhD3; Bradley C. Johnston, PhD3,29; Regina Kunz, MD, MSc24; Xin Sun, PhD3,5; Norman Buckley, MD1,2; Daniel I. Sessler, MD30; Gordon H. Guyatt, MD, MSc3 Author Affiliations
  • 1Michael G. DeGroote Institute for Pain Research and Care, McMaster University, Hamilton, Ontario, Canada
  • 2Department of Anesthesia, McMaster University, Hamilton, Ontario, Canada
  • 3Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada
  • 4Michael G. DeGroote Centre for Medicinal Cannabis Research, McMaster University, Hamilton, Ontario, Canada
  • 5Chinese Cochrane Centre, West China Hospital, Sichuan University, Chengdu
  • 6Faculty of Medicine, Ain Shams University, Cairo, Egypt
  • 7Department of Family Medicine, McMaster University, Hamilton, Ontario, Canada
  • 8Krembil Research Institute, University Health Network, University of Toronto, Toronto, Ontario, Canada
  • 9Now with the Canadian Agency for Drugs and Technologies in Health (CADTH), Toronto, Ontario, Canada
  • 10Pharmaceutical Science, University of Sorocaba, Sao Paulo, Brazil
  • 11Leonardo Hirslanden Klinik Birshof, Münchenstein, Switzerland
  • 12Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada
  • 13Department of Internal Medicine, Hospital Alemán de Buenos Aires, Buenos Aires, Argentina
  • 14Department of Anesthesiology and Pain Medicine, University of Ottawa, Ottawa, Ontario, Canada
  • 15Department of Anesthesiology, Perioperative and Pain Medicine, University of Calgary, Calgary, Alberta, Canada
  • 16Department of Family Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, Canada
  • 17Department of Anesthesia, University of Toronto, Toronto, Ontario, Canada
  • 18Department of Medicine, University of Toronto, Toronto, Ontario, Canada
  • 19Accident and Emergency Department, Queen Mary Hospital, Pokfulam, Hong Kong, China
  • 20Accident and Emergency Department, Tuen Mun Hospital, Hong Kong, China
  • 21Department of Medicine, Gjøvik, Innlandet Hospital Trust, Norway
  • 22Department of Hygiene and Dietetics, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland
  • 23Institute for Clinical Epidemiology and Biostatistics, University of Basel Hospital, Basel, Switzerland
  • 24Department of Clinical Research, University of Basel Hospital, Basel, Switzerland.
  • 25Department of Anesthesiology, Operative Intensive Care, Preclinical Emergency Medicine and Pain Management, University of Basel Hospital, Basel, Switzerland
  • 26Isfahan Medical Education Research Centre, Isfahan University of Medical Sciences, Isfahan, Iran
  • 27Canadian Academy of Osteopathy, Hamilton, Ontario, Canada
  • 28Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
  • 29Department of Community Health and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada
  • 30Department of Outcomes Research, Anesthesiology Institute, Cleveland Clinic, Cleveland, Ohio
 Read article on JAMA Network
editorial comment icon
Editorial
Comment
 related articles icon
Related
Articles
 author interview icon
Interviews
 multimedia icon
Multimedia
Video (2:40)
How Effective are Opioids for Chronic Noncancer Pain?
Read Article Take Quiz
Key Points

Question  Is the use of opioids to treat chronic noncancer pain associated with greater benefits or harms compared with placebo and alternative analgesics?

Findings  In this meta-analysis that included 96 randomized clinical trials and 26 169 patients with chronic noncancer pain, the use of opioids compared with placebo was associated with significantly less pain (−0.69 cm on a 10-cm scale) and significantly improved physical functioning (2.04 of 100 points), but the magnitude of the association was small. Opioid use was significantly associated with increased risk of vomiting.

Meaning  Opioids may provide benefit for chronic noncancer pain, but the magnitude is likely to be small.

Abstract

Importance  Harms and benefits of opioids for chronic noncancer pain remain unclear.

Objective  To systematically review randomized clinical trials (RCTs) of opioids for chronic noncancer pain.

Data Sources and Study Selection  The databases of CENTRAL, CINAHL, EMBASE, MEDLINE, AMED, and PsycINFO were searched from inception to April 2018 for RCTs of opioids for chronic noncancer pain vs any nonopioid control.

Data Extraction and Synthesis  Paired reviewers independently extracted data. The analyses used random-effects models and the Grading of Recommendations Assessment, Development and Evaluation to rate the quality of the evidence.

Main Outcomes and Measures  The primary outcomes were pain intensity (score range, 0-10 cm on a visual analog scale for pain; lower is better and the minimally important difference [MID] is 1 cm), physical functioning (score range, 0-100 points on the 36-item Short Form physical component score [SF-36 PCS]; higher is better and the MID is 5 points), and incidence of vomiting.

Results  Ninety-six RCTs including 26 169 participants (61% female; median age, 58 years [interquartile range, 51-61 years]) were included. Of the included studies, there were 25 trials of neuropathic pain, 32 trials of nociceptive pain, 33 trials of central sensitization (pain present in the absence of tissue damage), and 6 trials of mixed types of pain. Compared with placebo, opioid use was associated with reduced pain (weighted mean difference [WMD], −0.69 cm [95% CI, −0.82 to −0.56 cm] on a 10-cm visual analog scale for pain; modeled risk difference for achieving the MID, 11.9% [95% CI, 9.7% to 14.1%]), improved physical functioning (WMD, 2.04 points [95% CI, 1.41 to 2.68 points] on the 100-point SF-36 PCS; modeled risk difference for achieving the MID, 8.5% [95% CI, 5.9% to 11.2%]), and increased vomiting (5.9% with opioids vs 2.3% with placebo for trials that excluded patients with adverse events during a run-in period). Low- to moderate-quality evidence suggested similar associations of opioids with improvements in pain and physical functioning compared with nonsteroidal anti-inflammatory drugs (pain: WMD, −0.60 cm [95% CI, −1.54 to 0.34 cm]; physical functioning: WMD, −0.90 points [95% CI, −2.69 to 0.89 points]), tricyclic antidepressants (pain: WMD, −0.13 cm [95% CI, −0.99 to 0.74 cm]; physical functioning: WMD, −5.31 points [95% CI, −13.77 to 3.14 points]), and anticonvulsants (pain: WMD, −0.90 cm [95% CI, −1.65 to −0.14 cm]; physical functioning: WMD, 0.45 points [95% CI, −5.77 to 6.66 points]).

Conclusions and Relevance  In this meta-analysis of RCTs of patients with chronic noncancer pain, evidence from high-quality studies showed that opioid use was associated with statistically significant but small improvements in pain and physical functioning, and increased risk of vomiting compared with placebo. Comparisons of opioids with nonopioid alternatives suggested that the benefit for pain and functioning may be similar, although the evidence was from studies of only low to moderate quality.

Sign in to take quiz and track your certificates

Buy This Activity
Trending Audio
Cardiology
Subclinical Hypothyroidism
JAMA
Cancer Screening, Prevention, Control
USPSTF Recommendation: Screening for Pancreatic Cancer
JAMA
Guidelines
Screening for Hepatitis B Virus Infection in Pregnant Women
JAMA
Adolescent Medicine
Guns and Suicide
JAMA

See More About

Pain Medicine Opioids Substance Use and Addiction
Article Information

Corresponding Author: Jason W. Busse, DC, PhD, Department of Anesthesia, Michael G. DeGroote School of Medicine, McMaster University, HSC-2V9, 1280 Main St W, Hamilton, ON L8S 4K1, Canada (bussejw@mcmaster.ca).

Accepted for Publication: October 30, 2018.

Author Contributions: Drs Busse and Wang had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Busse, Schandelmaier, Johnston, Buckley, Sessler, Guyatt.

Acquisition, analysis, or interpretation of data: Busse, Wang, Kamaleldin, Craigie, Riva, Montoya, Mulla, Lopes, Vogel, Chen, Kirmayr, De Oliveira, Olivieri, Kaushal, Chaparro, Oyberman, Agarwal, Couban, Tsoi, Lam, Vandvik, Hsu, Bala, Schandelmaier, Scheidecker, Ebrahim, Ashoorion, Rehman, Hong, Sun, Buckley, Guyatt.

Drafting of the manuscript: Busse, Craigie, Kirmayr, Oyberman, Ebrahim, Johnston.

Critical revision of the manuscript for important intellectual content: Busse, Wang, Kamaleldin, Craigie, Riva, Montoya, Mulla, Lopes, Vogel, Chen, De Oliveira, Olivieri, Kaushal, Chaparro, Agarwal, Couban, Tsoi, Lam, Vandvik, Hsu, Bala, Schandelmaier, Scheidecker, Ebrahim, Ashoorion, Rehman, Hong, Sun, Buckley, Sessler, Guyatt.

Statistical analysis: Wang.

Obtained funding: Busse, Johnston, Buckley.

Administrative, technical, or material support: Kamaleldin, Craigie, Riva, Lopes, Vogel, Kirmayr, De Oliveira, Olivieri, Kaushal, Chaparro, Oyberman, Agarwal, Couban, Lam, Vandvik, Hsu, Ebrahim, Rehman, Hong.

Supervision: Busse, Craigie, Vandvik, Buckley.

Conflict of Interest Disclosures: Dr Buckley reported receiving personal fees from Purdue Pharma and Nova Scotia College of Physicians and Surgeons. No other disclosures were reported.

Funding/Support: This study was supported by grant 119801 from the Canadian Institutes of Health Research and grant 1516-HQ-000017 from Health Canada. Dr Riva is supported by a PhD training award from the NCMIC Foundation.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: We thank Wichor Bramer, BSc (Erasmus University Medical Center), Brian Alper, MD, MSPH, FAAFP (DynaMed Plus, EBSCO Health), and Neera Bhatnagar, BSc, MLiS (McMaster University Health Sciences Library), for peer review of the MEDLINE search strategy. We thank Yaping Chang, PhD (Department of Health Research Methods, Evidence, and Impact, McMaster University), Yvgeniy Oparin, BHSc (Michael G. DeGroote School of Medicine, McMaster University), Kayli Culig, BHSc (Faculty of Medicine, University of Toronto), Raad Yameen, MD (Institute of Medical Sciences, University of Toronto and Department of Family Medicine, University of Manitoba), Curtis May, BKin (Faculty of Medicine, University of British Columbia), Anna Goshua, BHSc (Faculty of Health Sciences, McMaster University), Annie Lok, HBA, MHE (Faculty of Health Sciences, McMaster University), and Regina Li, HBA, MSc (Faculty of Health Sciences, McMaster University) for screening citations. We thank Norman Buckley, MD (Department of Anesthesia, McMaster University), Dwight Moulin, MD (Department of Clinical Neurological Sciences, Western University), David Juurlink, MD, PhD (Departments of Medicine and Pediatrics, University of Toronto), Sol Stern, MD (Argus Medical Centre, Oakville), and Lydia Hatcher, MD (Department of Family Medicine, St Joseph’s Healthcare Hamilton), for review and feedback regarding the morphine equianalgesic table. We thank Linn Brandt, MD (Department of Internal Medicine, Gjøvik Sykehus, Sykehuset Innlandet Hospital Trust), Jan Brozek, MD, PhD (Department of Health Research Methods, Evidence, and Impact, McMaster University), Eva Dobos, MD (Szeged University of Medicine), Toshiaki A. Furukawa, MD, PhD (Departments of Health Promotion and Human Behavior and of Clinical Epidemiology, Kyoto University Graduate School of Medicine/School of Public Health), Andrea Rita Horvath, MD, PhD (Department of Clinical Chemistry and Endocrinology, New South Wales Health Pathology), Roman Jaeschke, MD, MSc (Department of Medicine, McMaster University), Annette Kristiansen, MD (Department of Health and Science, University of Oslo), Frances LeBlanc, DC (New Brunswick Chiropractic Association), Giovanna Lurati Buse, MD, MSc (Basel University Hospital), Irene Marzona, Pharmacy DR, MSc (IRCCS-Istituto di Ricerche Farmacologiche Mario Negri), Marek Nemec, MD (Department of Emergency Medicine, Basel University Hospital), Josef Prazak MD, PhD (Bern University Hospital), Dmitry Shiktorov, MD (Canadian Centre for Clinical Trials), Aran Tajika, MD (Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health), Brian Younho Hong, BHSc (Department of Medicine, University of Ottawa), and Konstantin Tikhonov, MD (University Health Network, Toronto), for screening the full texts of non-English articles. No financial compensation was provided to any of these individuals.

References
1.
Dahlhamer  J, Lucas  J, Zelaya  C,  et al.  Prevalence of chronic pain and high-impact chronic pain among adults—United States, 2016.  MMWR Morb Mortal Wkly Rep. 2018;67(36):1001-1006. doi:10.15585/mmwr.mm6736a2PubMedGoogle ScholarCrossref
2.
Van Zee  A.  The promotion and marketing of oxycontin: commercial triumph, public health tragedy.  Am J Public Health. 2009;99(2):221-227. doi:10.2105/AJPH.2007.131714PubMedGoogle ScholarCrossref
3.
Volkow  ND, McLellan  AT.  Opioid abuse in chronic pain.  N Engl J Med. 2016;374(13):1253-1263. doi:10.1056/NEJMra1507771PubMedGoogle ScholarCrossref
4.
Dowell  D, Haegerich  TM, Chou  R.  CDC guideline for prescribing opioids for chronic pain—United States, 2016.  MMWR Recomm Rep. 2016;65(1):1-49. doi:10.15585/mmwr.rr6501e1PubMedGoogle ScholarCrossref
5.
International Narcotics Control Board. Narcotic drugs: estimated world requirements for 2017: statistics for 2015. https://www.incb.org/documents/Narcotic-Drugs/Technical-Publications/2016/Narcotic_Drugs_Publication_2016.pdf. Accessed October 25, 2018.
6.
International Narcotics Control Board. Narcotic drugs: estimated world requirements for 2018: statistics for 2016. https://www.incb.org/documents/Narcotic-Drugs/Technical-Publications/2017/Narcotic_drugs_technical_publication_2017.pdf. Accessed October 25, 2018.
7.
Centers for Disease Control and Prevention. Key messages: prescription opioid data. https://www.cdc.gov/drugoverdose/data/prescribing.html. Accessed October 25, 2018.
8.
Han  B, Compton  WM, Jones  CM, Cai  R.  Nonmedical prescription opioid use and use disorders among adults aged 18 through 64 years in the United States, 2003-2013.  JAMA. 2015;314(14):1468-1478. doi:10.1001/jama.2015.11859PubMedGoogle ScholarCrossref
9.
Vowles  KE, McEntee  ML, Julnes  PS,  et al.  Rates of opioid misuse, abuse, and addiction in chronic pain.  Pain. 2015;156(4):569-576. doi:10.1097/01.j.pain.0000460357.01998.f1PubMedGoogle ScholarCrossref
10.
Ray  WA, Chung  CP, Murray  KT,  et al.  Prescription of long-acting opioids and mortality in patients with chronic noncancer pain.  JAMA. 2016;315(22):2415-2423. doi:10.1001/jama.2016.7789PubMedGoogle ScholarCrossref
11.
Chou  R, Turner  JA, Devine  EB,  et al.  The effectiveness and risks of long-term opioid therapy for chronic pain.  Ann Intern Med. 2015;162(4):276-286. doi:10.7326/M14-2559PubMedGoogle ScholarCrossref
12.
Furlan  A, Chaparro  LE, Irvin  E, Mailis-Gagnon  A.  A comparison between enriched and nonenriched enrollment randomized withdrawal trials of opioids for chronic noncancer pain.  Pain Res Manag. 2011;16(5):337-351. doi:10.1155/2011/465281PubMedGoogle ScholarCrossref
13.
Busse  JW, Bartlett  SJ, Dougados  M,  et al.  Optimal strategies for reporting pain in clinical trials and systematic reviews.  J Rheumatol. 2015;42(10):1962-1970. doi:10.3899/jrheum.141440PubMedGoogle ScholarCrossref
14.
Sun  X, Briel  M, Walter  SD, Guyatt  GH.  Is a subgroup effect believable? updating criteria to evaluate the credibility of subgroup analyses.  BMJ. 2010;340:c117. doi:10.1136/bmj.c117PubMedGoogle ScholarCrossref
15.
Moher  D, Liberati  A, Tetzlaff  J, Altman  DG; PRISMA Group.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.  Int J Surg. 2010;8(5):336-341. doi:10.1016/j.ijsu.2010.02.007PubMedGoogle ScholarCrossref
16.
Busse  JW, Schandelmaier  S, Kamaleldin  M,  et al.  Opioids for chronic non-cancer pain.  Syst Rev. 2013;2(66):66. doi:10.1186/2046-4053-2-66PubMedGoogle ScholarCrossref
17.
Turk  DC, Dworkin  RH, Allen  RR,  et al.  Core outcome domains for chronic pain clinical trials: IMMPACT recommendations.  Pain. 2003;106(3):337-345. doi:10.1016/j.pain.2003.08.001PubMedGoogle ScholarCrossref
18.
Turk  DC, Dworkin  RH, Revicki  D,  et al.  Identifying important outcome domains for chronic pain clinical trials.  Pain. 2008;137(2):276-285. doi:10.1016/j.pain.2007.09.002PubMedGoogle ScholarCrossref
19.
Goshua  A, Craigie  S, Guyatt  GH,  et al.  Patient values and preferences regarding opioids for chronic noncancer pain: a systematic review  [published online November 22, 2017].  Pain Med. doi:10.1093/pm/pnx274PubMedGoogle Scholar
20.
Nielsen  S, Degenhardt  L, Hoban  B, Gisev  N.  A synthesis of oral morphine equivalents (OME) for opioid utilisation studies.  Pharmacoepidemiol Drug Saf. 2016;25(6):733-737. doi:10.1002/pds.3945PubMedGoogle ScholarCrossref
21.
Tendal  B, Nüesch  E, Higgins  JP, Jüni  P, Gøtzsche  PC.  Multiplicity of data in trial reports and the reliability of meta-analyses: empirical study.  BMJ. 2011;343:d4829. doi:10.1136/bmj.d4829PubMedGoogle ScholarCrossref
22.
Akl  EA, Sun  X, Busse  JW,  et al.  Specific instructions for estimating unclearly reported blinding status in randomized trials were reliable and valid.  J Clin Epidemiol. 2012;65(3):262-267. doi:10.1016/j.jclinepi.2011.04.015PubMedGoogle ScholarCrossref
23.
Higgins  JP, Altman  DG, Gøtzsche  PC,  et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials.  BMJ. 2011;343:d5928. doi:10.1136/bmj.d5928PubMedGoogle ScholarCrossref
24.
Landis  JR, Koch  GG.  The measurement of observer agreement for categorical data.  Biometrics. 1977;33(1):159-174. doi:10.2307/2529310PubMedGoogle ScholarCrossref
25.
Thorlund  K, Walter  SD, Johnston  BC,  et al.  Pooling health-related quality of life outcomes in meta-analysis—a tutorial and review of methods for enhancing interpretability.  Res Synth Methods. 2011;2(3):188-203. doi:10.1002/jrsm.46PubMedGoogle ScholarCrossref
26.
Schünemann  HJ, Guyatt  GH.  Commentary—goodbye M(C)ID! hello MID, where do you come from?  Health Serv Res. 2005;40(2):593-597. doi:10.1111/j.1475-6773.2005.0k375.xPubMedGoogle ScholarCrossref
27.
Dworkin  RH, Turk  DC, Wyrwich  KW,  et al.  Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations.  J Pain. 2008;9(2):105-121. doi:10.1016/j.jpain.2007.09.005PubMedGoogle ScholarCrossref
28.
Ward  MM, Guthrie  LC, Alba  MI.  Clinically important changes in Short Form 36 health survey scales for use in rheumatoid arthritis clinical trials.  Arthritis Care Res (Hoboken). 2014;66(12):1783-1789. doi:10.1002/acr.22392PubMedGoogle ScholarCrossref
29.
Murad  MH, Montori  VM, Ioannidis  JPA, Prasad  K, Cook  DJ, Guyatt  GH. Fixed-effects and random-effects models. In:  Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. 3rd ed. New York, NY: McGraw-Hill Education; 2015:507-514.
30.
IntHout  J, Ioannidis  JP, Borm  GF.  The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method.  BMC Med Res Methodol. 2014;14:25. doi:10.1186/1471-2288-14-25PubMedGoogle ScholarCrossref
31.
Gelman  A, Hill  J. Missing-data imputation. In:  Data Analysis Using Regression and Multilevel/Hierarchical Models. New York, NY: Cambridge University Press; 2007:529-543.
32.
Busse  JW, Craigie  S, Juurlink  DN,  et al.  Guideline for opioid therapy and chronic noncancer pain.  CMAJ. 2017;189(18):E659-E666. doi:10.1503/cmaj.170363PubMedGoogle ScholarCrossref
33.
Guyatt  GH, Oxman  AD, Vist  GE,  et al; GRADE Working Group.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.  BMJ. 2008;336(7650):924-926. doi:10.1136/bmj.39489.470347.ADPubMedGoogle ScholarCrossref
34.
Higgins  JPT, Green  S, eds. Cochrane Handbook for Systematic Reviews of Interventions: version 5.1.0; updated March 2011. http://handbook-5-1.cochrane.org/. Accessed October 25, 2018.
35.
Begg  CB, Mazumdar  M.  Operating characteristics of a rank correlation test for publication bias.  Biometrics. 1994;50(4):1088-1101. doi:10.2307/2533446PubMedGoogle ScholarCrossref
36.
Caldwell  JR, Hale  ME, Boyd  RE,  et al.  Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs.  J Rheumatol. 1999;26(4):862-869.PubMedGoogle Scholar
37.
Cloutier  C, Taliano  J, O’Mahony  W,  et al.  Controlled-release oxycodone and naloxone in the treatment of chronic low back pain: a placebo-controlled, randomized study  [published correction appears in Pain Res Manag. 2013;18(6):328].  Pain Res Manag. 2013;18(2):75-82. doi:10.1155/2013/164609PubMedGoogle ScholarCrossref
38.
Hale  ME, Zimmerman  TR, Eyal  E, Malamut  R.  Efficacy and safety of a hydrocodone extended-release tablet formulated with abuse-deterrence technology in patients with moderate-to-severe chronic low back pain.  J Opioid Manag. 2015;11(6):507-518. doi:10.5055/jom.2015.0304PubMedGoogle ScholarCrossref
39.
Jamison  RN, Raymond  SA, Slawsby  EA, Nedeljkovic  SS, Katz  NP.  Opioid therapy for chronic noncancer back pain: a randomized prospective study.  Spine (Phila Pa 1976). 1998;23(23):2591-2600. doi:10.1097/00007632-199812010-00014PubMedGoogle ScholarCrossref
40.
Khoromi  S, Cui  L, Nackers  L, Max  MB.  Morphine, nortriptyline and their combination vs placebo in patients with chronic lumbar root pain.  Pain. 2007;130(1-2):66-75. doi:10.1016/j.pain.2006.10.029PubMedGoogle ScholarCrossref
41.
Webster  LR, Butera  PG, Moran  LV,  et al.  Oxytrex minimizes physical dependence while providing effective analgesia.  J Pain. 2006;7(12):937-946. doi:10.1016/j.jpain.2006.05.005PubMedGoogle ScholarCrossref
42.
Gimbel  J, Spierings  EL, Katz  N,  et al.  Efficacy and tolerability of buccal buprenorphine in opioid-experienced patients with moderate to severe chronic low back pain  [published correction appears in Pain. 2017;158(12):2366].  Pain. 2016;157(11):2517-2526. doi:10.1097/j.pain.0000000000000670PubMedGoogle ScholarCrossref
43.
Afilalo  M, Etropolski  MS, Kuperwasser  B,  et al.  Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee.  Clin Drug Investig. 2010;30(8):489-505. doi:10.2165/11533440-000000000-00000PubMedGoogle ScholarCrossref
44.
Arai  T, Kashimoto  Y, Ukyo  Y, Tominaga  Y, Imanaka  K.  Two placebo-controlled, randomized withdrawal studies to evaluate the fentanyl 1 day patch in opioid-naïve patients with chronic pain.  Curr Med Res Opin. 2015;31(12):2207-2218. doi:10.1185/03007995.2015.1092127PubMedGoogle ScholarCrossref
45.
Babul  N, Noveck  R, Chipman  H,  et al.  Efficacy and safety of extended-release, once-daily tramadol in chronic pain.  J Pain Symptom Manage. 2004;28(1):59-71. doi:10.1016/j.jpainsymman.2003.11.006PubMedGoogle ScholarCrossref
46.
Bennett  RM, Kamin  M, Karim  R, Rosenthal  N.  Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain.  Am J Med. 2003;114(7):537-545. doi:10.1016/S0002-9343(03)00116-5PubMedGoogle ScholarCrossref
47.
Breivik  H, Ljosaa  TM, Stengaard-Pedersen  K,  et al.  A 6-months, randomised, placebo-controlled evaluation of efficacy and tolerability of a low-dose 7-day buprenorphine transdermal patch in osteoarthritis patients naïve to potent opioids.  Scand J Pain. 2010;1(3):122-141. doi:10.1016/j.sjpain.2010.05.035PubMedGoogle ScholarCrossref
48.
Burch  F, Fishman  R, Messina  N,  et al.  A comparison of the analgesic efficacy of tramadol contramid OAD versus placebo in patients with pain due to osteoarthritis.  J Pain Symptom Manage. 2007;34(3):328-338. doi:10.1016/j.jpainsymman.2006.11.017PubMedGoogle ScholarCrossref
49.
Buynak  R, Shapiro  DY, Okamoto  A,  et al.  Efficacy and safety of tapentadol extended release for the management of chronic low back pain.  Expert Opin Pharmacother. 2010;11(11):1787-1804. doi:10.1517/14656566.2010.497720PubMedGoogle ScholarCrossref
50.
Christoph  A, Eerdekens  MH, Kok  M,  et al.  Cebranopadol, a novel first-in-class analgesic drug candidate.  Pain. 2017;158(9):1813-1824. doi:10.1097/j.pain.0000000000000986PubMedGoogle ScholarCrossref
51.
DeLemos  BP, Xiang  J, Benson  C,  et al.  Tramadol hydrochloride extended-release once-daily in the treatment of osteoarthritis of the knee and/or hip.  Am J Ther. 2011;18(3):216-226. doi:10.1097/MJT.0b013e3181cec307PubMedGoogle ScholarCrossref
52.
Emkey  R, Rosenthal  N, Wu  SC,  et al.  Efficacy and safety of tramadol/acetaminophen tablets (ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug.  J Rheumatol. 2004;31(1):150-156.PubMedGoogle Scholar
53.
Fishman  RL, Kistler  CJ, Ellerbusch  MT,  et al.  Efficacy and safety of 12 weeks of osteoarthritic pain therapy with once-daily tramadol (tramadol contramid OAD).  J Opioid Manag. 2007;3(5):273-280. doi:10.5055/jom.2007.0015PubMedGoogle ScholarCrossref
54.
Fleischmann  RM, Caldwell  JR, Roth  SH,  et al.  Tramadol for the treatment of joint pain associated with osteoarthritis.  Curr Ther Res Clin Exp. 2001;62(2):113-128. doi:10.1016/S0011-393X(01)80021-7Google ScholarCrossref
55.
Friedmann  N, Klutzaritz  V, Webster  L.  Efficacy and safety of an extended-release oxycodone (remoxy) formulation in patients with moderate to severe osteoarthritic pain.  J Opioid Manag. 2011;7(3):193-202. doi:10.5055/jom.2011.0062PubMedGoogle ScholarCrossref
56.
Gana  TJ, Pascual  ML, Fleming  RR,  et al.  Extended-release tramadol in the treatment of osteoarthritis.  Curr Med Res Opin. 2006;22(7):1391-1401. doi:10.1185/030079906X115595PubMedGoogle ScholarCrossref
57.
Hale  M, Khan  A, Kutch  M, Li  S.  Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain.  Curr Med Res Opin. 2010;26(6):1505-1518. doi:10.1185/03007995.2010.484723PubMedGoogle ScholarCrossref
58.
Hale  ME, Ahdieh  H, Ma  T,  et al.  Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients.  J Pain. 2007;8(2):175-184. doi:10.1016/j.jpain.2006.09.011PubMedGoogle ScholarCrossref
59.
Hanna  M, O’Brien  C, Wilson  MC.  Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.  Eur J Pain. 2008;12(6):804-813. doi:10.1016/j.ejpain.2007.12.010PubMedGoogle ScholarCrossref
60.
Katz  N, Hale  M, Morris  D, Stauffer  J.  Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain.  Postgrad Med. 2010;122(4):112-128. doi:10.3810/pgm.2010.07.2179PubMedGoogle ScholarCrossref
61.
Katz  N, Kopecky  EA, OʼConnor  M, Brown  RH, Fleming  AB.  A phase 3, multicenter, randomized, double-blind, placebo-controlled, safety, tolerability, and efficacy study of Xtampza ER in patients with moderate-to-severe chronic low back pain.  Pain. 2015;156(12):2458-2467. doi:10.1097/j.pain.0000000000000315PubMedGoogle ScholarCrossref
62.
Katz  N, Rauck  R, Ahdieh  H,  et al.  A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain.  Curr Med Res Opin. 2007;23(1):117-128. doi:10.1185/030079906X162692PubMedGoogle ScholarCrossref
63.
Mayorga  AJ, Wang  S, Kelly  KM, Thipphawong  J.  Efficacy and safety of fulranumab as monotherapy in patients with moderate to severe, chronic knee pain of primary osteoarthritis.  Int J Clin Pract. 2016;70(6):493-505. doi:10.1111/ijcp.12807PubMedGoogle ScholarCrossref
64.
Peloso  PM, Fortin  L, Beaulieu  A,  et al.  Analgesic efficacy and safety of tramadol/acetaminophen combination tablets (ultracet) in treatment of chronic low back pain.  J Rheumatol. 2004;31(12):2454-2463.PubMedGoogle Scholar
65.
Rauck  R, Rapoport  R, Thipphawong  J.  Results of a double-blind, placebo-controlled, fixed-dose assessment of once-daily OROS® hydromorphone ER in patients with moderate to severe pain associated with chronic osteoarthritis.  Pain Pract. 2013;13(1):18-29. doi:10.1111/j.1533-2500.2012.00555.xPubMedGoogle ScholarCrossref
66.
Rauck  RL, Hale  ME, Bass  A,  et al.  A randomized double-blind, placebo-controlled efficacy and safety study of ALO-02 (extended-release oxycodone surrounding sequestered naltrexone) for moderate-to-severe chronic low back pain treatment.  Pain. 2015;156(9):1660-1669. doi:10.1097/j.pain.0000000000000230PubMedGoogle ScholarCrossref
67.
Rauck  RL, Nalamachu  S, Wild  JE,  et al.  Single-entity hydrocodone extended-release capsules in opioid-tolerant subjects with moderate-to-severe chronic low back pain.  Pain Med. 2014;15(6):975-985. doi:10.1111/pme.12377PubMedGoogle ScholarCrossref
68.
Rauck  RL, Potts  J, Xiang  Q, Tzanis  E, Finn  A.  Efficacy and tolerability of buccal buprenorphine in opioid-naive patients with moderate to severe chronic low back pain.  Postgrad Med. 2016;128(1):1-11. doi:10.1080/00325481.2016.1128307PubMedGoogle ScholarCrossref
69.
Ruoff  GE, Rosenthal  N, Jordan  D,  et al.  Tramadol/acetaminophen combination tablets for the treatment of chronic lower back pain.  Clin Ther. 2003;25(4):1123-1141. doi:10.1016/S0149-2918(03)80071-1PubMedGoogle ScholarCrossref
70.
Schwartz  S, Etropolski  M, Shapiro  DY,  et al.  Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy.  Curr Med Res Opin. 2011;27(1):151-162. doi:10.1185/03007995.2010.537589PubMedGoogle ScholarCrossref
71.
Serrie  A, Lange  B, Steup  A.  Tapentadol prolonged-release for moderate-to-severe chronic osteoarthritis knee pain.  Curr Med Res Opin. 2017;33(8):1423-1432. doi:10.1080/03007995.2017.1335189PubMedGoogle ScholarCrossref
72.
Simpson  RW, Wlodarczyk  JH.  Transdermal buprenorphine relieves neuropathic pain.  Diabetes Care. 2016;39(9):1493-1500. doi:10.2337/dc16-0123PubMedGoogle ScholarCrossref
73.
Steiner  DJ, Sitar  S, Wen  W,  et al.  Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain.  J Pain Symptom Manage. 2011;42(6):903-917. doi:10.1016/j.jpainsymman.2011.04.006PubMedGoogle ScholarCrossref
74.
Tominaga  Y, Koga  H, Uchida  N,  et al.  Methodological issues in conducting pilot trials in chronic pain as randomized, double-blind, placebo-controlled studies.  Drug Res (Stuttg). 2016;66(7):363-370. doi:10.1055/s-0042-107669PubMedGoogle ScholarCrossref
75.
Trenkwalder  C, Chaudhuri  KR, Martinez-Martin  P,  et al.  Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson’s disease (PANDA).  Lancet Neurol. 2015;14(12):1161-1170. doi:10.1016/S1474-4422(15)00243-4PubMedGoogle ScholarCrossref
76.
Vinik  AI, Shapiro  DY, Rauschkolb  C,  et al.  A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy.  Diabetes Care. 2014;37(8):2302-2309. doi:10.2337/dc13-2291PubMedGoogle ScholarCrossref
77.
Vojtaššák  J, Vojtaššák  J, Jacobs  A,  et al.  A phase IIIb, multicentre, randomised, parallel-group, placebo-controlled, double-blind study to investigate the efficacy and safety of OROS hydromorphone in subjects with moderate-to-severe chronic pain induced by osteoarthritis of the hip or the knee.  Pain Res Treat. 2011;2011:239501.PubMedGoogle Scholar
78.
Vorsanger  GJ, Xiang  J, Gana  TJ,  et al.  Extended-release tramadol (tramadol ER) in the treatment of chronic low back pain.  J Opioid Manag. 2008;4(2):87-97. doi:10.5055/jom.2008.0013PubMedGoogle ScholarCrossref
79.
Weil  AJ, Masters  ET, Barsdorf  AI,  et al.  Patient-reported health-related quality of life, work productivity, and activity impairment during treatment with ALO-02 (extended-release oxycodone and sequestered naltrexone) for moderate-to-severe chronic low back pain.  Health Qual Life Outcomes. 2017;15(1):202. doi:10.1186/s12955-017-0749-yPubMedGoogle ScholarCrossref
80.
Wen  W, Sitar  S, Lynch  SY, He  E, Ripa  SR.  A multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of single-entity, once-daily hydrocodone tablets in patients with uncontrolled moderate to severe chronic low back pain.  Expert Opin Pharmacother. 2015;16(11):1593-1606. doi:10.1517/14656566.2015.1060221PubMedGoogle ScholarCrossref
81.
Caldwell  JR, Rapoport  RJ, Davis  JC,  et al.  Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain.  J Pain Symptom Manage. 2002;23(4):278-291. doi:10.1016/S0885-3924(02)00383-4PubMedGoogle ScholarCrossref
82.
Chu  LF, D’Arcy  N, Brady  C,  et al.  Analgesic tolerance without demonstrable opioid-induced hyperalgesia.  Pain. 2012;153(8):1583-1592. doi:10.1016/j.pain.2012.02.028PubMedGoogle ScholarCrossref
83.
Freeman  R, Raskin  P, Hewitt  DJ,  et al; CAPSS-237 Study Group.  Randomized study of tramadol/acetaminophen versus placebo in painful diabetic peripheral neuropathy.  Curr Med Res Opin. 2007;23(1):147-161. doi:10.1185/030079906X162674PubMedGoogle ScholarCrossref
84.
Gilron  I, Bailey  JM, Tu  D,  et al.  Morphine, gabapentin, or their combination for neuropathic pain.  N Engl J Med. 2005;352(13):1324-1334. doi:10.1056/NEJMoa042580PubMedGoogle ScholarCrossref
85.
Gilron  I, Tu  D, Holden  RR,  et al.  Combination of morphine with nortriptyline for neuropathic pain.  Pain. 2015;156(8):1440-1448. doi:10.1097/j.pain.0000000000000149PubMedGoogle ScholarCrossref
86.
Gimbel  JS, Richards  P, Portenoy  RK.  Controlled-release oxycodone for pain in diabetic neuropathy.  Neurology. 2003;60(6):927-934. doi:10.1212/01.WNL.0000057720.36503.2CPubMedGoogle ScholarCrossref
87.
Gordon  A, Callaghan  D, Spink  D,  et al.  Buprenorphine transdermal system in adults with chronic low back pain.  Clin Ther. 2010;32(5):844-860. doi:10.1016/j.clinthera.2010.04.018PubMedGoogle ScholarCrossref
88.
Gordon  A, Rashiq  S, Moulin  DE,  et al.  Buprenorphine transdermal system for opioid therapy in patients with chronic low back pain.  Pain Res Manag. 2010;15(3):169-178. doi:10.1155/2010/216725PubMedGoogle ScholarCrossref
89.
Harati  Y, Gooch  C, Swenson  M,  et al.  Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy.  Neurology. 1998;50(6):1842-1846. doi:10.1212/WNL.50.6.1842PubMedGoogle ScholarCrossref
90.
Langford  R, McKenna  F, Ratcliffe  S,  et al.  Transdermal fentanyl for improvement of pain and functioning in osteoarthritis.  Arthritis Rheum. 2006;54(6):1829-1837. doi:10.1002/art.21884PubMedGoogle ScholarCrossref
91.
Lee  JH, Lee  CS; Ultracet ER Study Group.  A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of the extended-release tramadol hydrochloride/acetaminophen fixed-dose combination tablet for the treatment of chronic low back pain.  Clin Ther. 2013;35(11):1830-1840. doi:10.1016/j.clinthera.2013.09.017PubMedGoogle ScholarCrossref
92.
Ma  K, Jiang  W, Zhou  Q, Du  DP.  The efficacy of oxycodone for management of acute pain episodes in chronic neck pain patients.  Int J Clin Pract. 2008;62(2):241-247. doi:10.1111/j.1742-1241.2007.01567.xPubMedGoogle ScholarCrossref
93.
Matsumoto  AK, Babul  N, Ahdieh  H.  Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis.  Pain Med. 2005;6(5):357-366. doi:10.1111/j.1526-4637.2005.00057.xPubMedGoogle ScholarCrossref
94.
Moran  C.  MST continus tablets and pain control in severe rheumatoid arthritis.  Br J Clin Res. 1991;2:1-12.Google Scholar
95.
Peloso  PM, Bellamy  N, Bensen  W,  et al.  Double blind randomized placebo control trial of controlled release codeine in the treatment of osteoarthritis of the hip or knee.  J Rheumatol. 2000;27(3):764-771.PubMedGoogle Scholar
96.
Thorne  C, Beaulieu  AD, Callaghan  DJ,  et al.  A randomized, double-blind, crossover comparison of the efficacy and safety of oral controlled-release tramadol and placebo in patients with painful osteoarthritis.  Pain Res Manag. 2008;13(2):93-102. doi:10.1155/2008/165421PubMedGoogle ScholarCrossref
97.
Uberall  MA, Mueller-Schwefe  GH, Terhaag  B.  Efficacy and safety of flupirtine modified release for the management of moderate to severe chronic low back pain.  Curr Med Res Opin. 2012;28(10):1617-1634. doi:10.1185/03007995.2012.726216PubMedGoogle ScholarCrossref
98.
Zin  CS, Nissen  LM, O’Callaghan  JP,  et al.  A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin.  J Pain. 2010;11(5):462-471. doi:10.1016/j.jpain.2009.09.003PubMedGoogle ScholarCrossref
99.
Chen  L, Sein  M, Vo  T,  et al.  Clinical interpretation of opioid tolerance versus opioid-induced hyperalgesia.  J Opioid Manag. 2014;10(6):383-393. doi:10.5055/jom.2014.0235PubMedGoogle ScholarCrossref
100.
Salsitz  EA.  Chronic pain, chronic opioid addiction: a complex nexus.  J Med Toxicol. 2016;12(1):54-57. doi:10.1007/s13181-015-0521-9PubMedGoogle ScholarCrossref
101.
Ballantyne  JC.  Opioid therapy in chronic pain.  Phys Med Rehabil Clin N Am. 2015;26(2):201-218. doi:10.1016/j.pmr.2014.12.001PubMedGoogle ScholarCrossref
102.
Juurlink  DN.  Rethinking “doing well” on chronic opioid therapy.  CMAJ. 2017;189(39):E1222-E1223. doi:10.1503/cmaj.170628PubMedGoogle ScholarCrossref
103.
Häuser  W, Schug  S, Furlan  AD.  The opioid epidemic and national guidelines for opioid therapy for chronic noncancer pain.  Pain Rep. 2017;2(3):e599. doi:10.1097/PR9.0000000000000599PubMedGoogle ScholarCrossref
104.
Macfarlane  GJ, Kronisch  C, Dean  LE,  et al.  EULAR revised recommendations for the management of fibromyalgia.  Ann Rheum Dis. 2017;76(2):318-328. doi:10.1136/annrheumdis-2016-209724PubMedGoogle ScholarCrossref
105.
Ballantyne  JC.  Avoiding opioid analgesics for treatment of chronic low back pain.  JAMA. 2016;315(22):2459-2460. doi:10.1001/jama.2016.6753PubMedGoogle ScholarCrossref
106.
Abdel Shaheed  C, Maher  CG, Williams  KA,  et al.  Efficacy, tolerability, and dose-dependent effects of opioid analgesics for low back pain.  JAMA Intern Med. 2016;176(7):958-968. doi:10.1001/jamainternmed.2016.1251PubMedGoogle ScholarCrossref
107.
Guyatt  GH, Juniper  EF, Walter  SD,  et al.  Interpreting treatment effects in randomised trials.  BMJ. 1998;316(7132):690-693. doi:10.1136/bmj.316.7132.690PubMedGoogle ScholarCrossref
108.
Naliboff  BD, Wu  SM, Schieffer  B,  et al.  A randomized trial of 2 prescription strategies for opioid treatment of chronic nonmalignant pain.  J Pain. 2011;12(2):288-296. doi:10.1016/j.jpain.2010.09.003PubMedGoogle ScholarCrossref
109.
Gomes  T, Mamdani  MM, Paterson  JM,  et al.  Trends in high-dose opioid prescribing in Canada.  Can Fam Physician. 2014;60(9):826-832.PubMedGoogle Scholar
110.
Fernandes  K, Martins  D, Juurlink  D,  et al.  High-dose opioid prescribing and opioid-related hospitalization.  PLoS One. 2016;11(12):e0167479. doi:10.1371/journal.pone.0167479PubMedGoogle ScholarCrossref
111.
Edlund  MJ, Martin  BC, Devries  A,  et al.  Trends in use of opioids for chronic noncancer pain among individuals with mental health and substance use disorders.  Clin J Pain. 2010;26(1):1-8. doi:10.1097/AJP.0b013e3181b99f35PubMedGoogle ScholarCrossref
112.
Davis  MA, Lin  LA, Liu  H, Sites  BD.  Prescription opioid use among adults with mental health disorders in the United States.  J Am Board Fam Med. 2017;30(4):407-417. doi:10.3122/jabfm.2017.04.170112PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right

Name Your Search

Save Search
Privacy Policy|Terms of Use
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Topics
State Requirements
Privacy Policy | Terms of Use
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue